← All companies

Science / Company profile

Owkin

What Owkin does

Owkin is an agentic AI company focused on biomedical R&D, building “K Pro,” an AI agent for biology that is powered by multimodal patient data and designed to support decisions across drug discovery, drug development, and diagnostics. In Owkin’s framing, K Pro is an “AI Scientist” that orchestrates specialized AI skills to decode complex biology and accelerate research, with scientists shaping hypotheses and outputs. K Pro is positioned for both (1) pharma/biopharma R&D teams making pipeline and program decisions and (2) clinical research and academic partners that need interoperable, privacy-preserving access to real-world multimodal data. Owkin’s strategy emphasizes the combination of multimodal patient datasets (including spatial/multi-omics), federated/partner data networks, and agentic workflows that connect research insights to clinical validation and use-cases (for example, tumor boards and biomarker validation in partner hospitals).

News

Company record

Aug 07, 2026 · Official · OwkinOwkin and CRO Aviano Sign Master Partnership Agreement to Foster Collaborative Oncology Research

Owkin and Aviano’s cancer institute (CRO) announced a master partnership agreement aimed at facilitating collaborative oncology research projects, leveraging Owkin’s agentic AI approach for biology and drug discovery and development workflows.

Aug 06, 2026 · Official · OwkinOwkin to Integrate Kognitic's Clinical Trial Data Into K Pro Through New Collaboration

Owkin announced a data collaboration with Kognitic to integrate Kognitic’s clinical trial data into K Pro, expanding how K Pro can learn from and operate over clinical trial information.

Jul 21, 2026 · Official · OwkinOwkin and Gustave Roussy partner to bring K Pro into real-world clinical practice

Owkin and Gustave Roussy announced a partnership to test K Pro within the hospital’s real-world clinical and research workflows, with an initial focus on molecular tumor boards and support for evidence surfacing and interpretation for individual patients.

Jun 05, 2026 · Official · OwkinOwkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi

Owkin announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, described as being backed by a five-year license for K Pro.

May 13, 2026 · Official · OwkinOwkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement with AstraZeneca

Owkin announced a multi-year K Pro license arrangement with AstraZeneca in which Owkin would build custom biopharma AI agents intended to support AstraZeneca decision-making workflows.

Mar 12, 2026 · Official · OwkinOwkin creates new spin out Waiv, formerly Owkin Dx, with $33m financing

Owkin announced the spin-out of Waiv (formerly Owkin Dx), positioning Waiv as focused on AI-powered precision testing and describing Owkin’s prior incubation activity through Bioptimus as part of a broader patient validation strategy.

Mar 04, 2026 · Official · OwkinOwkin Announces Partnership with Consensus to Strengthen Literature Intelligence for Owkin’s AI Scientist, K Pro

Owkin announced a partnership with Consensus to bring enhanced scientific literature intelligence into K Pro, describing that answers could be grounded in large volumes of peer-reviewed scientific articles via full-text integrations with controls around recency and citations.

Mar 03, 2026 · Official · OwkinNHS Lothian joins Owkin’s patient data network with multi-year partnership

Owkin announced that NHS Lothian joined its patient data network via a multi-year partnership intended to strengthen Owkin’s multimodal data discovery and agentic AI infrastructure.

Show 4 earlier updates
Aug 19, 2025 · Official · OwkinOwkin and The Comprehensive Cancer Center of the Medical University of Vienna Announce Strategic Collaboration to Accelerate Cancer Research and Care with AI Copilot

Owkin announced a strategic collaboration with the Medical University of Vienna’s comprehensive cancer center and University Hospital Vienna for deployment of Owkin K (described as an AI copilot for biology), aiming to support clinicians and researchers with agentic AI tools within the oncology ecosystem.

Jul 29, 2025 · Official · OwkinOwkin Teams Up with NeoGenomics and France Tissue Bank to Build IHC-Dedicated Foundation Model for AI-Driven ADC Diagnostics

Owkin announced an agreement with NeoGenomics and France Tissue Bank to develop an immunohistochemistry (IHC)-focused foundation model trained on IHC images, positioning the model for ADC diagnostics research use.

Jul 01, 2025 · Official · OwkinOwkin partners with Hôpital Foch to validate its tumor biomarkers on human biological samples

Owkin announced a framework agreement with Hôpital Foch to test and validate biomarkers discovered through Owkin’s AI on human tumor samples, describing evaluation via post-surgical tissue and in vitro assessment workflows.

Feb 27, 2025 · Official · OwkinOwkin launches ATLANTIS: An extensive multimodal patient data discovery program across 7 countries in 11 therapeutic areas

Owkin announced ATLANTIS, a multimodal patient data mapping/discovery program intended to unlock data access across institutions, with a stated completion target and an aim to power K Pro with the discovered multimodal datasets.

Source map · 2 recurring channels · 21 references

Still resolving: Newsroom · Official X

Funding

Latest disclosed valuation$1B
Tracked capital$505.2M6 sourced rounds
DateRoundRaisedValuationLead / investorsEvidence
Jun 07, 2022Series B (Bristol Myers Squibb equity investment as part of collaboration)$80M
Not attributed
+1 investor
Nov 18, 2021Series B$180M$1B
Not attributed
+2 investors
Oct 01, 2018Seed$2.1M
Not attributed
Oct 01, 2016Seed$2.1M
Not attributed

What it builds

K Pro

K Pro is Owkin’s agentic AI platform for biology that is powered by multimodal patient data and positioned to support biopharma decision-making across the pipeline. Owkin describes K Pro as an orchestrator of specialized AI skills (for example, target prioritization, patient subgroup characterization, biomarker validation across modalities, and reports designed to be publication-ready) and notes support for deployments on customer infrastructure with security/compliance claims.

source ↗
K Pro Free

K Pro Free is described by Owkin as a public/free version of K Pro intended for exploration and demo on public data, with a limited usage tier.

source ↗
K Pro (advanced)

Owkin describes K Pro (advanced version) as the enhanced offering for pharmaceutical teams with access to proprietary datasets and higher usage levels.

source ↗
MCP integration / skills framework

Owkin documents that K Pro connects to external tools and agents via a skills framework and supports MCP integration as described in its K Pro product documentation.

source ↗
Owkin K (co-pilot/co-pilot roadmap in product documentation)

Owkin documentation describes “Owkin K” as an agentic AI co-pilot driving insight generation and decision-making to accelerate breakthroughs and advance drug discovery, development, and diagnostics, powered by multimodal patient data and a bring-your-own-data capability.

source ↗

Key metrics

Milestones & partnerships

Aug 06, 2026
Clinical-trial data integration into K Pro via Kognitic collaboration

Owkin announced a data collaboration intended to integrate Kognitic’s clinical trial data into K Pro.

Kognitic
Jul 21, 2026
Real-world clinical workflow testing of K Pro at Gustave Roussy

Owkin began testing K Pro within real-world clinical and research workflows at Gustave Roussy, with an initial focus on molecular tumor boards.

Gustave Roussy
Jun 05, 2026
Sanofi collaboration expansion to build biopharma AI agents

Owkin announced a multi-year Sanofi collaboration to co-develop next-generation biopharma agents backed by a five-year K Pro license.

Sanofi
Mar 12, 2026
Spin-out of Waiv (formerly Owkin Dx) to pursue AI-powered precision testing

Owkin spun out Waiv (formerly Owkin Dx) following investor interest, positioning it as focused on clinical precision testing and biomarker outcome prediction.

Mar 04, 2026
Consensus integration for grounded literature intelligence in K Pro

Owkin announced partnership with Consensus to provide literature intelligence into K Pro workflows, grounded in scientific articles.

Consensus
Jul 01, 2025
Biomarker validation framework agreement with Hôpital Foch

Owkin and Hôpital Foch announced a framework agreement to validate AI-discovered biomarkers using human tumor samples.

Hôpital Foch
Feb 27, 2025
Launch of ATLANTIS multimodal patient data discovery program

Owkin launched ATLANTIS as a multimodal patient data discovery/mapping initiative across countries and therapeutic areas intended to power its agentic systems.

Feb 20, 2024
Bioptimus seed financing (Owkin-incubated company) to build biology-focused AI foundation model

Owkin announced Bioptimus raising $35M seed financing for a biology-focused AI foundation model, describing Bioptimus as incubated by Owkin.